DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF
DBV Technologies S.A.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 16, 2026
$8.97−0.08 (-0.88%)
Close on Oct 19, 2026
- Market cap
- $3.89B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.98 (−47.08%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
DBV Technologies S.A. grew revenue 29.3% to $5.02M over the twelve months to Jun 30, 2026. Free cash flow was -$170.61M.
Revenue
$5.02M
+29.3% vs. a year earlier
Operating income
-$177.83M
TTM Q2 2026
Free cash flow
-$170.61M
TTM Q2 2026
EPS, diluted
-$0.71
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.89B
- P/E ratio
- –
- Price to sales
- 774.82
- Price to book
- 24.24
- Dividend yield
- –
- Free cash flow yield
- -4.39%
Fundamentals
- Revenue
- $5.02M
- Net income
- -$175.99M
- EPS, diluted
- -$0.71
- Free cash flow
- -$170.61M
- Book value per share
- $0.37
- Diluted shares
- 434M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$5.02M+29.3% YoY
Operating income
-$177.83M
Net income
-$175.99M
EPS, diluted
-$0.71
Free cash flow
-$170.61M
Reported periodTrailing twelve months